QIAGEN’s QuantiFERON-TB® Gold Plus wins UN migration agency’s tender

Hilden, Germany, and Germantown, Maryland, July 30, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON-TB® Gold Plus (QFT-Plus), the gold standard in accurate, cost-effective testing for latent tuberculosis (TB) infection, has been adopted by the International Organization for Migration (IOM) for use in screening migrants for the infection. As the United... Read more

PerkinElmer’s EUROIMMUN Receives FDA Clearance for ANCA IFA and EUROPLUS Granulocyte Mosaic™ assays using EUROPattern Microscope

Assist in Screening and Diagnosing ANCA-Associated Vasculitis WALTHAM, Mass. – July 25, 2018 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that its EUROIMMUN ANCA IFA and EUROPLUS Granulocyte Mosaic™ assays for use with EUROPattern microscope have received 510(k) clearance from the U.S. Food & Drug Administration (FDA).... Read more

FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease

Basel, 20 July 2018 FDA grants Breakthrough Device Designation for Roche’s Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer’s disease Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF.... Read more

FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease

Basel, 20 July 2018 FDA grants Breakthrough Device Designation for Roche’s Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer’s disease Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF.... Read more

GE, Lagos State Government Sign Agreement on Power, Healthcare, Skills Development

Lagos, Nigeria – July 4, 2018: GE (NYSE: GE), the world’s premier digital industrial company and the Lagos State Government have agreed to pool their resources for the development of critical infrastructure in the state in the areas of Power, Healthcare and Skills Development. This was announced during the signing of a Support and Cooperation Agreement... Read more

AMETEK Grabner Instruments and Agilent Technologies Provide an Innovative Mobile Testing Solution for the Petroleum Industry

Wednesday, July 18, 2018 Vienna, Austria – AMETEK Grabner Instruments and Agilent Technologies Inc. announce an OEM agreement for an innovative mobile testing solution for in-the-field analysis of lubricating oils and greases. Grabner Instruments, based in Austria, is well known for developing and manufacturing automatic petroleum testing equipment. In this partnership, Grabner will focus on lube... Read more

Agilent and Grabner Instruments Provide Innovative Mobile Testing Solution for the Petroleum Industry

Agilent and Grabner Instruments Provide Innovative Mobile Testing Solution for the Petroleum Industry SANTA CLARA, Calif., July 18, 2018 Agilent Technologies Inc. (NYSE: A) announces an equipment manufacturing agreement with Grabner Instruments, a subsidiary of AMETEK, Inc. The agreement is focused on an innovative mobile testing solution for in-field analysis of lubricating oils and greases.... Read more

FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)

Basel, 18 July 2018 FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab)... Read more

FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)

Basel, 18 July 2018 FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab)... Read more

Teledyne CETAC Technologies Introduces the Next Generation Homogenizing Autosampler for Oils Applications

Introducing the next generation of automation for oils, wear oils and coolants for sample introduction for ICP-OES… The ‘Oils 7400’ Homogenizing Autosampler Omaha, NE USA / July 2, 2018 – Teledyne CETAC introduces the next generation homogenizing autosampler for oils, wear oils and coolants for sample introduction for ICP-OES.  The Oils 7400 Homogenizing Autosampler is... Read more